Md Nurunnabi to Antineoplastic Agents
This is a "connection" page, showing publications Md Nurunnabi has written about Antineoplastic Agents.
Connection Strength
2.166
-
Kumar R, Afrin H, Bhatt HN, Beaven E, Gangavarap A, Esquivel SV, Zahid MI, Nurunnabi M. Mucoadhesive Carrier-Mediated Oral Co-delivery of Bcl2 Inhibitors Improves Gastric Cancer Treatment. ACS Appl Mater Interfaces. 2024 Jan 10; 16(1):305-317.
Score: 0.549
-
Bhatt HN, Diwan R, Borrego EA, P?rez CAM, Varela-Ramirez A, Kumar R, Aguilera RJ, Nurunnabi M. A photothermal driven chemotherapy for the treatment of metastatic melanoma. J Control Release. 2023 09; 361:314-333.
Score: 0.534
-
Afrin H, Huda MN, Islam T, Oropeza BP, Alvidrez E, Abir MI, Boland T, Turbay D, Nurunnabi M. Detection of Anticancer Drug-Induced Cardiotoxicity Using VCAM1-Targeted Nanoprobes. ACS Appl Mater Interfaces. 2022 Aug 24; 14(33):37566-37576.
Score: 0.498
-
Huda MN, Deaguero IG, Borrego EA, Kumar R, Islam T, Afrin H, Varela-Ramirez A, Aguilera RJ, Tanner EEL, Nurunnabi M. Ionic liquid-mediated delivery of a BCL-2 inhibitor for topical treatment of skin melanoma. J Control Release. 2022 09; 349:783-795.
Score: 0.498
-
Khatun Z, Nurunnabi M, Reeck GR, Cho KJ, Lee YK. Oral delivery of taurocholic acid linked heparin-docetaxel conjugates for cancer therapy. J Control Release. 2013 Aug 28; 170(1):74-82.
Score: 0.066
-
Khatun Z, Choi YS, Kim YG, Yoon K, Nurunnabi M, Li L, Lee E, Kang HC, Huh KM. Bioreducible Poly(ethylene glycol)-Triphenylphosphonium Conjugate as a Bioactivable Mitochondria-Targeting Nanocarrier. Biomacromolecules. 2017 04 10; 18(4):1074-1085.
Score: 0.021